Reduces serum phosphorus. ANDA 203179, held by Mpp Pharma. Calcium Acetate.
As of Nov 16, 2026, ANDA 203179 (Calcium Acetate), held by Mpp Pharma, was first approved by FDA on Oct 26, 2015, with 0 approved supplements and 0 published complete response letters.
1. INDICATIONS & USAGE Calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). Calcium acetate capsules are a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Calcium Acetate667MG · capsule;oral | Calcium Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters